Article Text

Download PDFPDF
Communications
Genome-wide significant association of ANKRD55 rs6859219 and multiple sclerosis risk

Statistics from Altmetric.com

Footnotes

  • Contributors Study design and supervision: CML, FZ, KV and LB. Data acquisition and performing of experiments: CML, B-MMS, CG, VD, DAA, PB, L-AG, AK, FL, IC-R, SH, AW, ET, FP, PC, DO, AAn, AAl, MC, XM, JO, FM, TD, S-CL, ES-T, UL, AC, PR, H-PH, OA, PL, MB, TK, CK, UKZ, JTE and BF. Data analysis and interpretation of results: CML, TL, KV and LB. Writing of manuscript: CML and LB with the help of all coauthors.

  • Funding This project was funded by grants from the German Ministry for Education and Research (BMBF) and German Research Foundation (DFG; to FZ), the BMBF and the Cure Alzheimer's Fund (to LB), the Walter- and Ilse-Rose-Stiftung (to H-PH and OA), the BMBF (grant NBL3 to UKZ; grant 01UW0808 to UL and ES-T), and the Innovation Fund of the Max Planck Society (M.FE.A.BILD0002 to UL). This project was supported by INSERM, ARSEP, AFM and GIS-IBISA. CML was supported by the Fidelity Biosciences Research Initiative.

  • Competing interests LA Gerdes reports to have received travel expenses and personal compensation from Merck Serono, Teva Pharmaceutical Industries, Bayer Schering Pharma, Novartis and Biogen Idec. T Kl reports to have received travel expenses and personal compensations from Bayer Schering Pharmacy, Teva, Merck-Serono, Novartis, Sanofi-Aventis and Biogen-Idec as well as grant support from Bayer-Schering AG. None of the other authors reports any disclosures.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.